Irisin‐Encapsulated Mitochondria‐Targeted Biomimetic Nanotherapeutics for Alleviating Acute Kidney Injury
Advanced Science · 2024-10 · 11 (38)
DOI: 10.1002/advs.202402805 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 09.08.2024. Verfasst von Xia Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, 400042, P. R. China. Hauptthemen laut MEDLINE: Acute Kidney Injury, Mitochondria, Fibronectins, Disease Models, Animal. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chongqing Science and Technology Bureau, National Key R&D Program of China.
Abstract (Originalsprache)
Acute kidney injury (AKI) is the sudden decrease in renal function that can be attributed to dysregulated reactive oxygen species (ROS) production and impaired mitochondrial function. Irisin, a type I membrane protein secreted by skeletal muscles in response to physical activity, has been reported to alleviate kidney damage through regulation of mitochondrial biogenesis and oxidative metabolism. In this study, a macrophage membrane‐coated metal‐organic framework (MCM@MOF) is developed as a nanocarrier for encapsulating irisin to overcome the inherent characteristics of irisin, including a short circulation time, limited kidney‐targeting ability, and low membrane permeability. The engineered irisin‐mediated biomimetic nanotherapeutics have extended circulation time and enhanced targeting capability toward injured kidneys due to the preservation of macrophage membrane proteins. The irisin‐encapsulated biomimetic nanotherapeutics effectively mitigate acute ischemia‐reperfusion injury by protecting mitochondrial function and modulating SOD2 levels in renal tubular epithelial cells. The present study provides novel insights to advance the development of irisin as a potential therapeutic approach for AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, 400042, P. R. China.
- Key Laboratory of Geriatric Cardiovascular and Cerebrovascular Disease Research, Ministry of Education of China, Chongqing, 400042, P. R. China.
- Chongqing Key Laboratory for Hypertension Research, Cardiovascular Clinical Research Center, Chongqing Institute of Cardiology, Chongqing, 400042, P. R. China.
- Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, Chongqing, 400714, P. R. China.
- Chongqing General Hospital, Chongqing, 401147, P. R. China.
- Division of Renal Diseases & Hypertension, Department of Medicine and Pharmacology-Physiology, The George Washington University School of Medicine & Health Sciences, Washington DC, 20037, USA.
ORCID-Profile: Lijia Liang, Chunyu Zeng
Förderung
- National Natural Science Foundation of China
- Chongqing Science and Technology Bureau
- National Key R&D Program of China
- National Key Research and Development Program of China
Zitieren
APA
Zhang, X., Liang, L., Wang, F., Jose, P. A., Chen, K., & Zeng, C. (2024). Irisin‐Encapsulated Mitochondria‐Targeted Biomimetic Nanotherapeutics for Alleviating Acute Kidney Injury. Advanced Science, 11(38). https://doi.org/10.1002/advs.202402805
Vancouver
Zhang X, Liang L, Wang F, Jose PA, Chen K, Zeng C. Irisin‐Encapsulated Mitochondria‐Targeted Biomimetic Nanotherapeutics for Alleviating Acute Kidney Injury. Advanced Science. 2024;11(38). doi:10.1002/advs.202402805
BibTeX
@article{Zhang2024,
author = {Zhang, Xia and Liang, Lijia and Wang, Fengxian and Jose, Pedro A and Chen, Ken and Zeng, Chunyu},
title = {Irisin‐Encapsulated Mitochondria‐Targeted Biomimetic Nanotherapeutics for Alleviating Acute Kidney Injury},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {38},
doi = {10.1002/advs.202402805}
}
EUVIMED